

# SmartNanoTox

## Five AOPs developed in SmartNanoTox

Ulla Vogel, NRCWE on behalf of SmartNanoTox partners



# Inhalation of particles cause several severe diseases

ORIGINAL ARTICLE

## Respiratory disease mortality among US coal miners; results after 37 years of follow-up

Judith M Graber,<sup>1,2</sup> Leslie T Stayner,<sup>1</sup> Robert A Cohen,<sup>3</sup> Lorraine M Conroy,<sup>3</sup> Michael D Attfield<sup>4</sup>

**Table 2** Overall and stratified SMRs for selected underlying causes of death and percentage of ever smokers, mean cumulative coal mine dust and respirable silica exposure category by coal-rank region, radiographic status at enrolment, race and calendar year of death



Category	Pneumoconiosis*		COPD		Lung cancer		Ever smoked at enrolment Per cent	Mean cumulative exposure*	
	Obs.	SMR	Obs.	SMR	Obs.	SMR		Coal mine dust mg/m <sup>3</sup> -years	Respirable silica
Total	403	79.70	309	1.11	568	1.08	79.6	81.0	3.2
Region									
Eastern Pennsylvania	181	365.29	11	0.61	26	0.79	77.0	97.7	2.6
Eastern Appalachia	65	86.91	48	1.26	77	1.01	82.4	77.4	2.8
Western Appalachia	101	38.21	157	1.05	334	1.17†	82.3	82.3	3.8
Midwest	14	17.38	53	1.44†	101	1.47†	86.7	72.8	2.7
West	42	53.74	40	1.10	30	0.49†	81.7	77.5	2.5
Race									
White	389	67.44	293	1.09	542	1.09†	82.5	80.4	3.3
Black	14	129.84	16	1.60	26	0.88	78.1	90.4	3.8
Baseline radiograph									
Category 0	237	48.50	250	1.06	510	1.13†	83.0	76.4	3.2
Category 1	56	92.67	29	1.15	39	0.89	78.9	99.3	3.6
Category 2	65	192.82	24	1.85†	14	0.62	75.7	113.0	3.6
Category 3	45	409.78	6	1.39	5	0.61	82.5	122.0	3.6
Calendar year of death									
1970–1989	170	63.25	85	0.86	233	0.95	83.60	n/a	
1990–1999	143	106.20	118	1.19	208	1.31†	81.90		
2000–2007	90	127.59	106	1.26†	127	1.23†	80.90		

\*SMRs from pneumoconiosis are artificially high as there is no valid comparison group in the general population. We included them to show comparisons within levels of covariates and for consistency with previously published studies of this cohort. We do not include statistical testing given the lack of a valid comparison group.

†Statistically significant at  $p < 0.05$ .

- 8827 miners
- 37 years of follow-up (1969/71-2007)
- 67% dead (cause of death known)

# Low clearance of inhaled nanoparticles from the lung




Marianne Dybdahl



Inhalation of nanomaterials has been linked to cancer, cardiovascular disease, and fibrosis

# Adverse Outcome Pathways as a tool to understand nanomaterial-induced toxicity




- An **adverse outcome pathway (AOP)** is structured representation of biological events leading to [adverse effects](#) and is considered relevant to [risk assessment](#)
- The AOP links in a linear way existing knowledge along one or more series of causally connected **key events (KE)** between two points — a **molecular initiating event (MIE)** and an **adverse outcome (AO)** that occur at a level of biological organization relevant to [risk assessment](#). The linkage between the events is described by **key event relationships (KER)** that describe the causal relationships between the key events.

# AOPs are useful in nanotoxicology




- Can be used to identify new, relevant AOs based on MIE or KE
- Identify and provide evidence for causal relationships between agent and disease for classification and labelling (regulation)
- Understanding of the underlying mechanism of action guides preventive measures in the working environment
- Understanding which physico-chemical properties that drive the toxic response guide safe-by-design approaches in innovation of new nanomaterials

## Five Nano-relevant AOPs developed in the EU H2020 project SmartNanoTox



# Fibrosis AOP 273 *(developed by Sabina Halappanavar)*


Sabina Halappanavar and Barbara Rothen-Rutishauser will discuss this AOP in their next talks today



Copied from:

Nikola J, Banville A, Goodwin LR, Wu D, Williams A, Yauk CL, Wallin H, Vogel U, Halappanavar S. [Stat-6 signaling pathway and not Interleukin-1 mediates multi-walled carbon nanotube-induced lung fibrosis in mice: insights from an adverse outcome pathway framework.](#) *Part Fibre Toxicol.* 2017 Sep 13;14(1):37.



# Interactions with lung tissues leading to lung fibrosis via a pathway involving Trefoil Factor 2



We propose that the presence of asbestos -like fibers causes damage to epithelial cells and macrophages in the lung (MIE) and, if the fibers persist, will cause a persistent TFF2 release (KE1) that in turn will cause the release of IL-33 (KE2) that will generate a Th2 type of milieu (KE3). Both the Th2 milieu and TFF2 will directly induce proliferation of fibroblast and myofibroblast and regeneration of epithelial cells (KE 4). Extracellular matrix is subsequently produced (KE5) leading to the AO of fibrosis. In addition to fibrosis, as this pathway includes regenerative events, we believe it is likely it is involved in carcinogenesis.



# AOP 303: Frustrated phagocytosis-induced lung cancer



# AOP237: Pulmonary acute phase response leading to CHD

NM Phys./Chem  
properties,  
shape, ...

Bio-nano-  
interface

Phys-chem

MIE


KE1

KE2

KE3

KE4

AO




## REVIEW



### Acute Phase Response as a Biological Mechanism-of-Action of (Nano)particle-Induced Cardiovascular Disease


Niels Hadrup, Vadim Zhemovkov, Nicklas Raun Jacobsen, Carola Voss, Maximilian Strunz, Meshal Ansari, Herbert B. Schiller, Sabina Halappanavar, Sarah S. Poulsen, Boris Kholodenko, Tobias Stoeger, Anne Thoustrup Saber, and Ulla Vogel\*

Open access: PMID: 32227434




# AOP302: Disruption of lung surfactant function – acute inhalation toxicity

Jorid Sørli, Janez Štrancar, Jesus Perez-Gil, Otmar Schmid, Ulla Vogel



# The AOPs are heavily interconnected and share KEs




# Summary

- SmartNanoTox has contributed to the development of five AOPs for nanomaterial-induced fibrosis, lung cancer, cardiovascular disease and acute lung toxicity
- 4 of the AOPs can be found at <https://aopwiki.org/>
- Further descriptions and discussions of the AOPs can be found in the open access review:  
[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7249325/pdf/12989\\_2020\\_Article\\_344.pdf](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7249325/pdf/12989_2020_Article_344.pdf)

Halappanavar et al. *Particle and Fibre Toxicology* (2020) 17:16  
<https://doi.org/10.1186/s12989-020-00344-4> Particle and Fibre Toxicology

**REVIEW** **Open Access**

Adverse outcome pathways as a tool for the design of testing strategies to support the safety assessment of emerging advanced materials at the nanoscale



Sabina Halappanavar<sup>1\*</sup>, Sybille van den Brule<sup>2</sup>, Penny Nymark<sup>3,4</sup>, Laurent Gaté<sup>5</sup>, Carole Seidel<sup>5</sup>, Sarah Valentino<sup>5</sup>, Vadim Zheronkov<sup>6</sup>, Pernille Høgh Danielsen<sup>7</sup>, Andrea De Vizcaya<sup>8,9</sup>, Henrik Wolff<sup>10</sup>, Tobias Stöger<sup>11,12,13</sup>, Andrey Boyadziev<sup>1</sup>, Sarah Søs Poulsen<sup>7</sup>, Jorid Birkelund Sørli<sup>7</sup> and Ulla Vogel<sup>7,14\*</sup>

Thank you for your attention!